trending Market Intelligence /marketintelligence/en/news-insights/trending/yN1s5YpNexdJkPXTvchEAw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Braslyn to acquire all minority-held shares of Callidus Capital

Street Talk Episode 56 - Latest bank MOE shows even the strong need scale to thrive

South State CenterState MOE Shows Even The Strong Need Scale To Thrive

Talking Bank Stocks, Playing The M&A Trade With Longtime Investor

Report: Kashkari Says Fed In Holding Pattern But Rate Cut Still Possible

Braslyn to acquire all minority-held shares of Callidus Capital

Braslyn Ltd. agreed to acquire all the minority-held shares of Callidus Capital Corp. that are not owned by funds managed by parent company Catalyst Capital Group and board directors Newton Glassman and James Riley.

The Catalyst Capital funds own around 72.2% of Callidus Capital's shares, according to a news release.

Braslyn will acquire the shares for 75 Canadian cents apiece, which represents an 82.9% premium to Callidus Capital's Aug. 15 closing price and a 62.3% premium to its 20-day volume weighted average trading price.

Braslyn entered into various voting agreements to gain support for the deal. Callidus Capital is allowed to negotiate with other parties for another acquisition proposal up until 5 p.m. ET on Aug. 29.

The deal is expected to close in the fourth quarter.

Braslyn, a unit of early stage venture capital firm Tavistock Life Sciences, in December 2018 proposed raising its stake in Callidus Capital by acquiring all shares not owned by Callidus and itself for C$2.00 apiece. Callidus Capital's board said it will respect the choice of its minority shareholders.

Tavistock Life Sciences owns a 14.52% stake in Callidus Capital, according to S&P Global Market Intelligence data, making it the second-largest shareholder.

Blair Franklin Capital Partners Inc. provided financial valuation advice to Callidus Capital's special committee, while MPA Morrison Park Advisors Inc. provided a fairness opinion.